Emphysema at Baseline Low-Dose CT Lung Cancer Screening Predicts Death from Chronic Obstructive Pulmonary Disease and Cardiovascular Disease Up to 25 Years Later.
IF 15.2
1区 医学
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Jessica González Gutiérrez,Rowena Yip,Javier J Zulueta,Samuel M Aguayo,Daniel M Libby,Mark W Pasmantier,David F Yankelevitz,Claudia I Henschke,
求助PDF
{"title":"Emphysema at Baseline Low-Dose CT Lung Cancer Screening Predicts Death from Chronic Obstructive Pulmonary Disease and Cardiovascular Disease Up to 25 Years Later.","authors":"Jessica González Gutiérrez,Rowena Yip,Javier J Zulueta,Samuel M Aguayo,Daniel M Libby,Mark W Pasmantier,David F Yankelevitz,Claudia I Henschke, ","doi":"10.1148/radiol.250949","DOIUrl":null,"url":null,"abstract":"Background The prognostic value of baseline visual emphysema scoring at low-dose CT (LDCT) in lung cancer screening cohorts is unknown. Purpose To determine whether a single visual emphysema score at LDCT is predictive of 25-year mortality from all causes, chronic obstructive pulmonary disease (COPD), and cardiovascular disease (CVD). Materials and Methods In this prospective cohort study, asymptomatic adults aged 40-85 years with a history of smoking underwent baseline LDCT screening for lung cancer between June 2000 and December 2008. Follow-up continued until death, loss to follow-up, or December 31, 2024. Emphysema was assessed at baseline LDCT and scored from 0 (none) to 3 (severe) by one of four experienced chest radiologists. Baseline smoking history and comorbidities were self-reported. Causes of death (International Classification of Diseases, 10th Revision) were obtained from the U.S. National Death Index, physicians, and family. Associations between emphysema and mortality were evaluated using adjusted Cox proportional hazards and adjusted Fine-Gray competing risks models. Results Among 9047 participants (4614 female; median age, 65 years [IQR, 61-69 years]; median pack-years of smoking, 43 [IQR, 28-64]), 2637 (29.1%) had emphysema (mild in 1908 [21.1%], moderate in 512 [5.7%], and severe in 217 [2.4%]). Median follow-up was 23.3 years. Emphysema was independently predictive of all-cause mortality (hazard ratio [HR], 1.29; 95% CI: 1.21, 1.38; P < .001), COPD mortality (HR, 3.29; 95% CI: 2.59, 4.18; P < .001), and CVD mortality (HR, 1.14; 95% CI: 1.01, 1.29; P = .04). A dose-response relationship was observed between emphysema severity and both all-cause and COPD mortality, but not CVD mortality. In the adjusted competing risk analysis, emphysema remained associated with COPD mortality (HR, 3.06; 95% CI: 2.40, 3.90; P < .001), but not CVD mortality (HR, 1.04; 95% CI: 0.91, 1.18; P = .59). Conclusion Baseline emphysema at LDCT in a prospective lung cancer screening cohort of asymptomatic adults was predictive of all-cause, COPD, and CVD mortality up to 25 years later. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Mascalchi and Diciotti in this issue.","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"24 1","pages":"e250949"},"PeriodicalIF":15.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1148/radiol.250949","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
Background The prognostic value of baseline visual emphysema scoring at low-dose CT (LDCT) in lung cancer screening cohorts is unknown. Purpose To determine whether a single visual emphysema score at LDCT is predictive of 25-year mortality from all causes, chronic obstructive pulmonary disease (COPD), and cardiovascular disease (CVD). Materials and Methods In this prospective cohort study, asymptomatic adults aged 40-85 years with a history of smoking underwent baseline LDCT screening for lung cancer between June 2000 and December 2008. Follow-up continued until death, loss to follow-up, or December 31, 2024. Emphysema was assessed at baseline LDCT and scored from 0 (none) to 3 (severe) by one of four experienced chest radiologists. Baseline smoking history and comorbidities were self-reported. Causes of death (International Classification of Diseases, 10th Revision) were obtained from the U.S. National Death Index, physicians, and family. Associations between emphysema and mortality were evaluated using adjusted Cox proportional hazards and adjusted Fine-Gray competing risks models. Results Among 9047 participants (4614 female; median age, 65 years [IQR, 61-69 years]; median pack-years of smoking, 43 [IQR, 28-64]), 2637 (29.1%) had emphysema (mild in 1908 [21.1%], moderate in 512 [5.7%], and severe in 217 [2.4%]). Median follow-up was 23.3 years. Emphysema was independently predictive of all-cause mortality (hazard ratio [HR], 1.29; 95% CI: 1.21, 1.38; P < .001), COPD mortality (HR, 3.29; 95% CI: 2.59, 4.18; P < .001), and CVD mortality (HR, 1.14; 95% CI: 1.01, 1.29; P = .04). A dose-response relationship was observed between emphysema severity and both all-cause and COPD mortality, but not CVD mortality. In the adjusted competing risk analysis, emphysema remained associated with COPD mortality (HR, 3.06; 95% CI: 2.40, 3.90; P < .001), but not CVD mortality (HR, 1.04; 95% CI: 0.91, 1.18; P = .59). Conclusion Baseline emphysema at LDCT in a prospective lung cancer screening cohort of asymptomatic adults was predictive of all-cause, COPD, and CVD mortality up to 25 years later. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Mascalchi and Diciotti in this issue.
基线低剂量CT肺癌筛查肺气肿预测25年后慢性阻塞性肺疾病和心血管疾病的死亡
背景低剂量CT (LDCT)基线视觉肺气肿评分在肺癌筛查队列中的预后价值尚不清楚。目的:确定LDCT单次目视肺气肿评分是否可预测25年全因死亡率、慢性阻塞性肺疾病(COPD)和心血管疾病(CVD)。材料和方法在这项前瞻性队列研究中,在2000年6月至2008年12月期间,年龄在40-85岁、有吸烟史的无症状成年人接受了基线LDCT肺癌筛查。随访持续至死亡、随访失败或2024年12月31日。在基线LDCT上评估肺气肿,并由四名经验丰富的胸科医生中的一名评分从0(无)到3(严重)。基线吸烟史和合并症均为自述。死亡原因(国际疾病分类,第十次修订)从美国国家死亡指数、医生和家庭获得。使用校正Cox比例风险和校正Fine-Gray竞争风险模型评估肺气肿与死亡率之间的关系。结果在9047名参与者中(4614名女性,中位年龄65岁[IQR, 61-69岁],中位吸烟包年43岁[IQR, 28-64]), 2637名(29.1%)患有肺气肿(1908名轻度[21.1%],512名中度[5.7%],217名重度[2.4%])。中位随访时间为23.3年。肺气肿是全因死亡率的独立预测指标(风险比[HR], 1.29; 95% CI: 1.21, 1.38; P < 0.001)、COPD死亡率(风险比,3.29;95% CI: 2.59, 4.18; P < 0.001)和CVD死亡率(风险比,1.14;95% CI: 1.01, 1.29; P = 0.04)。肺气肿严重程度与全因死亡率和COPD死亡率之间存在剂量-反应关系,但与CVD死亡率无关。在调整后的竞争风险分析中,肺气肿仍然与COPD死亡率相关(相对危险度,3.06;95% CI: 2.40, 3.90; P < 0.001),但与CVD死亡率无关(相对危险度,1.04;95% CI: 0.91, 1.18; P = 0.59)。结论:在一项前瞻性无症状成人肺癌筛查队列中,LDCT基线肺气肿可预测25年后全因、COPD和CVD死亡率。©RSNA, 2025本文可获得补充材料。参见Mascalchi和Diciotti在本期的社论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。